Component
Posterior tibial compound muscle action potential amplitude
Independent substance, clinical endpoint or measured readout; study context is retained with each finding.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
The primary posterior tibial CMAP endpoint showed a mean difference of -0.2 mV (95% CI -0.8 to 0.3); secondary nerve-conduction and cognitive outcomes also showed no significant benefit.
Experimental context and source evidence
- availability_state
- biomarker_context Imported condition classification; unverified.
- experimental_model
- Double-blind randomized trial: 201 adults aged at least 75 with B12 107–210 pmol/L, without anemia or relevant neurologic/cognitive signs; 191 had outcome assessment.
- exposure
- Oral cyanocobalamin 1 mg/day versus placebo for 12 months.
- limitations
- Null results have confidence limits; do not extrapolate to symptomatic deficiency.
- nutrient_topic
- Vitamin B12 research collection; topical membership is not evidence of a direct dietary effect. · Vitamin B12 (cobalamins)
- organism
- Homo sapiens
- plain_language
- Improved B12-related markers did not translate into measured neurologic or cognitive improvement in this asymptomatic group.
- primary_references
- [b12-dangour2015] Effects of vitamin B-12 supplementation on neurologic and cognitive function in older people: a randomized controlled trial (2015). https://pubmed.ncbi.nlm.nih.gov/26135351/ DOI: 10.3945/ajcn.115.110775
- tissue_or_cell_type
- Human blood or whole-person endpoints
- trigger_kind
- biomarker_context Imported condition classification; unverified.
Vitamin B12: mechanisms, deficiency and nutrient interactions (2026-09-17) · lines 1524–1534
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Double-blind randomized trial: 201 adults aged at least 75 with B12 107–210 pmol/L, without anemia or relevant neurologic/cognitive signs; 191 had outcome assessment. · source_derived_draft · unverified_draft
### b12-dangour-neural-null The primary posterior tibial CMAP endpoint showed a mean difference of -0.2 mV (95% CI -0.8 to 0.3); secondary nerve-conduction and cognitive outcomes also showed no significant benefit. Condition category: biomarker_context nutrient_topic: Vitamin B12 research collection; topical membership is not evidence of a direct dietary effect. plain_language: Improved B12-related markers did not translate into measured neurologic or cognitive improvement in this asymptomatic group. organism: Homo sapiens tissue_or_cell_type: Human blood or whole-person endpoints experimental_model: Double-blind randomized trial: 201 adults aged at least 75 with B12 107–210 pmol/L, without anemia or relevant neurologic/cognitive signs; 191 had outcome assessment. limitations: Null results have confidence limits; do not extrapolate to symptomatic deficiency. exposure: Oral cyanocobalamin 1 mg/day versus placebo for 12 months. [b12-dangour2015] Effects of vitamin B-12 supplementation on neurologic and cognitive function in older people: a randomized controlled trial (2015). https://pubmed.ncbi.nlm.nih.gov/26135351/ DOI: 10.3945/ajcn.115.110775
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.